The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Open accessAbstract
Importance: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. Objective: To determine whether the administration of adjuvant metformin (vs placebo) to patients with breast cancer without diabetes improves outcomes. Design, Setting, and Participants: MA.32, a phase 3 randomized, placebo-controlled, double-blind trial, conducted in Canada, Switzerland, US, and UK, enrolled 3649 patients with high-risk nonmetastatic breast cancer receiving standard therapy between August 2010 and March 2013, with follow-up to October 2020. Interventions: Patients were randomized (stratified for hormone receptor [estrogen receptor and/or progesterone receptor {ER/PgR}] status, positive vs negative; body mass index, ≤30 vs >30; human epidermal growth factor receptor 2 [ERBB2, formerly HER2 or HER2/neu], positive vs negative; and any vs no chemotherapy) to 850 mg of oral metformin twice a day (n = 1824) or oral placebo twice a day (n = 1825) for 5 years. Main Outcomes and Measures: The primary outcome was invasive disease-free survival in hormone receptor-positive breast cancer. Of the 8 secondary outcomes, overall survival, distant relapse-free survival, and breast cancer-free interval were analyzed. Results: Of the 3649 randomized patients (mean age, 52.4 years; 3643 women [99.8%]), all (100%) were included in analyses. After a second interim analysis, futility was declared for patients who were ER/PgR-, so the primary analysis was conducted for 2533 patients who were ER/PgR+. The median duration of follow-up in the ER/PgR+ group was 96.2 months (range, 0.2-121 months). Invasive disease-free survival events occurred in 465 patients who were ER/PgR+. The incidence rates for invasive disease-free survival events were 2.78 per 100 patient-years in the metformin group vs 2.74 per 100 patient-years in the placebo group (hazard ratio [HR], 1.01; 95% CI, 0.84-1.21; P = .93), and the incidence rates for death were 1.46 per 100 patient-years in the metformin group vs 1.32 per 100 patient-years in the placebo group (HR, 1.10; 95% CI, 0.86-1.41; P = .47). Among patients who were ER/PgR-, followed up for a median of 94.1 months, incidence of invasive disease-free survival events was 3.58 vs 3.60 per 100 patient-years, respectively (HR, 1.01; 95% CI, 0.79-1.30; P = .92). None of the 3 secondary outcomes analyzed in the ER/PgR+ group had statistically significant differences. Grade 3 nonhematological toxic events occurred more frequently in patients taking metformin than in patients taking placebo (21.5% vs 17.5%, respectively, P = .003). The most common grade 3 or higher adverse events in the metformin vs placebo groups were hypertension (2.4% vs 1.9%), irregular menses (1.5% vs 1.4%), and diarrhea (1.9% vs 7.0%). Conclusions and Relevance: Among patients with high-risk operable breast cancer without diabetes, the addition of metformin vs placebo to standard breast cancer treatment did not significantly improve invasive disease-free survival. Trial Registration: ClinicalTrials.gov Identifier: NCT01101438.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880
Research works printed but not linked: 25
- Xu, 2015, Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis., Oncologist, 20, 1236, 10.1634/theoncologist.2015-0096 · DOI
- Lega, 2013, Association between metformin therapy and mortality after breast cancer: a population-based study., Diabetes Care, 36, 3018, 10.2337/dc12-2535 · DOI
- Hosio, 2020, Survival after breast cancer in women with type 2 diabetes using antidiabetic medication and statins: a retrospective cohort study., Acta Oncol, 59, 1110, 10.1080/0284186X.2020.1769858 · DOI
- Sonnenblick, 2017, Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALLTO Phase III randomized trial., J Clin Oncol, 35, 1421, 10.1200/JCO.2016.69.7722 · DOI · Paper page
- Rahmani, 2020, The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials., Clin Transl Oncol, 22, 37, 10.1007/s12094-019-02108-9 · DOI
- Goodwin, 2021, Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial., NPJ Breast Cancer, 7, 74, 10.1038/s41523-021-00275-z · DOI
- Saini, 2018, Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells., Acta Biochim Biophys Sin (Shanghai), 50, 133, 10.1093/abbs/gmx106 · DOI · Paper page
- Dowling, 2012, Metformin in cancer: translational challenges., J Mol Endocrinol, 48, R31, 10.1530/JME-12-0007 · DOI · Paper page
- Bonanni, 2012, Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial., J Clin Oncol, 30, 2593, 10.1200/JCO.2011.39.3769 · DOI · Paper page
- Niraula, 2012, Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study., Breast Cancer Res Treat, 135, 821, 10.1007/s10549-012-2223-1 · DOI · Paper page
- Hadad, 2015, Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial., Breast Cancer Res Treat, 150, 149, 10.1007/s10549-015-3307-5 · DOI
- Kalinsky, 2014, Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer., Cancer Invest, 32, 150, 10.3109/07357907.2014.889706 · DOI
- Cuyàs, 2019, The C allele of ATM rs112112617 associates with pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin., Front Oncol, 9, 193, 10.3389/fonc.2019.00193 · DOI
- van Leeuwen, 2012, A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts., Diabetologia, 55, 1971, 10.1007/s00125-012-2537-x · DOI
- White, 1978, Allocation of patients to treatment groups in a controlled clinical study., Br J Cancer, 37, 849, 10.1038/bjc.1978.124 · DOI · Paper page
- Pimentel, 2021, The effect of metformin on sex hormones in Canadian Cancer Trials group MA.32., J Natl Cancer Inst, 113, 192, 10.1093/jnci/djaa082 · DOI
- Lohmann, 2017, Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32., Breast Cancer Res Treat, 164, 371, 10.1007/s10549-017-4265-x · DOI
- Goodwin, 2021, CA 15-3/MUC1 levels in CCTG MA.32: a breast cancer randomized trial of metformin vs placebo., JNCI Cancer Spectr, 5, 10.1093/jncics/pkab066 · DOI
- Hudis, 2007, Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system., J Clin Oncol, 25, 2127, 10.1200/JCO.2006.10.3523 · DOI · Paper page
- Chlebowski, 2006, Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study., J Natl Cancer Inst, 98, 1767, 10.1093/jnci/djj494 · DOI · Paper page
- Pimentel, 2019, A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy., Breast, 48, 17, 10.1016/j.breast.2019.08.003 · DOI
- Zhao, 2017, A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer., Oncotarget, 8, 84224, 10.18632/oncotarget.v8i48 · doi:10.18632/oncotarget.v8i48
- Nanni, 2019, Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer: the MYME randomized, phase 2 clinical trial., Breast Cancer Res Treat, 174, 433, 10.1007/s10549-018-05070-2 · DOI
- Peairs, 2011, Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis., J Clin Oncol, 29, 40, 10.1200/JCO.2009.27.3011 · DOI · Paper page
- Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies., Diabetes Care, 35, 2665, 10.2337/dc12-0788 · DOI · Paper page
Cited by
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 699
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Sleeboom, J. J. F., van Tienderen, G. S., Schenke-Layland, K., van der Laan, L. J. W., Khalil, A. A., & Verstegen, M. M. A. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3840 · Cited by 375
The role of lipid metabolic reprogramming in tumor microenvironment
Yang, K., Wang, X., Song, C., He, Z., Wang, R., Xu, Y., Jiang, G., Wan, Y., Mei, J., & Mao, W. (2023) · Theranostics · doi:10.7150/thno.82920 · Cited by 270
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Metadata
- Authors
- Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., Rea, D. W., Stos, P. M., Shepherd, L. E., Stambolic, V., & Parulekar, W. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-05-24
- Volume
- 327
- Issue
- 20
- Pages
- 1963
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4282916913
- Cited by
- 240
- References
- 2
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2022.6147
- The paper
- Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., . . . Parulekar, W. R. (2022). Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2022.6147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.